| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
6,152 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-60 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Theralink Technologies, Inc., previously known as OncBioMune Pharmaceuticals, Inc., was a clinical-stage biopharmaceutical company that focused on developing novel cancer immunotherapy products and had a proprietary vaccine technology. On June 5, 2020, Theralink Technologies, Inc. acquired the assets of Avant Diagnostics, Inc., a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of patented proprietary data-generating assays, through the Asset Sale Transaction. The company purchased substantially all of the assets of Avant, and assumed some of its liabilities. In consideration for the Asset Sale Transaction, Theralink Technologies, Inc. issued to Avant 1,000 shares of a newly created Series D-1 Preferred Stock, which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the effectiveness of an increase of the Companyes authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,549,184 shares of the Companyes common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction, and controlled the Companyes Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Therefore, the Asset Sale Transaction was accounted for as an asset acquisition of the Companyes net assets by Avant and a recapitalization of Avant.
On June 5, 2020, Theralink Technologies, Inc. entered into an employment agreement with Dr. Michael Ruxin to serve as the companyes Chief Executive Officer, President and a director, entered into an employment agreement with Jeffery Busch to serve as the companyes Chairman of the Board of Directors, and appointed Yvonne Fors to its Board of Directors, pursuant to the Asset Purchase Agreement. On August 14, 2020, the Board appointed Mr. Andrew Kucharchuk as Acting Chief Financial Officer of the Company, and approved a change in the Companyes fiscal year-end from December 31 to September 30, effective immediately for the current fiscal year, and for all subsequent years until such time as the Board resolves to amend such fiscal year-end. The fiscal year has been changed to conform to the September 30 fiscal year-end of Avant, which is the historical registrant as a result of the Asset Sale Transaction consummated on June 5, 2020, and therefore, no transition report is required.
On September 24, 2020, Andrew Kucharchuk resigned from his position as Acting Chief Financial Officer. Mr. Kucharchuk continues to serve as a director on the Companyes Board of Directors. On the same day, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. On April 1, 2022, the Board of Directors was expanded to six members, and Danica Holley and Matthew Schwartz were appointed to these newly created positions.
Theralink Technologies, Inc. is a commercial-stage, precision medicine, molecular data-generating company that focuses on the development and commercialization of a series of proprietary data-generating assays that may provide important actionable information for physicians, patients and biopharmaceutical companies, in the area of oncology. The Company aims to commercialize the technology originally developed by Theranostics Health, Inc. The technology is differentiated due to the exclusive license agreement with George Mason University (eGMUe), the patent portfolio licensed from GMU and the National Institute of Health (eNIHe), access to GMUes well-p.
In addition to its current product offerings, Theralink is also actively pursuing the development of new products, with a focus on expanding its precision oncology offerings. The company is working to develop assays that can be used to identify specific molecular targets that are associated with various types of cancer, with the goal of enabling more targeted and effective treatments for patients.
Theralink has also established partnerships with other companies in the biopharmaceutical industry, in order to leverage its proprietary technology to support drug development and clinical trials. Through these partnerships, Theralink aims to generate additional revenue streams and expand the reach of its technology into new areas of oncology research and treatment.
Overall, Theralink Technologies is a cutting-edge biopharmaceutical company with a focus on precision medicine and molecular data-generating assays for the diagnosis and treatment of cancer. With a strong patent portfolio and a team of experienced industry professionals, the company is well-positioned for continued growth and success in the years to come.
Company Address: 15000 W. 6th Avenue Golden 80401 CO
Company Phone Number: 420-0074 Stock Exchange / Ticker: OBMP
|
%
0.29%